Prognostic markers for kidney cancer

A recent study published in the Lancet Oncology has identified that the mutation status of three genes – BAP1, PBRM1, and TP53 – had independent prognostic value for patients with advanced or metastatic renal cell carcinoma (RCC) about to start treatment with first-line tyrosine kinase inhibitors (TKIs). The mutation status of these three genes is useful for helping to determine […]

read more

Exercise significantly cuts the risk of death from cancer

New research from an American group based at Roswell Park Comprehensive Cancer Center, New York shows that if cancer patients exercise regularly both before and after their diagnosis, they are significantly more likely to survive cancer than those who are sedentary. This adds to the growing evidence that physical activity is important for the prevention […]

read more

Cancer drugs taking longer to reach NHS patients

A new report by the Institute of Cancer Research (ICR) has found that patients are waiting longer for new cancer drugs to be approved for use with the NHS because of delays in clinical trials and regulatory approval for use. The report found that the average time taken from the start of phase I clinical […]

read more

First NHS cancer patient to begin treatment with proton beam therapy in Manchester

Cally Palmer, NHS England’s national cancer director announced at the Britain Against Cancer conference yesterday that the first patient in England is to begin state of the art proton beam therapy for cancer at The Christie Hospital in Manchester this month, marking a major milestone for NHS care. The second proton beam therapy machine is […]

read more

Comparison of axitinib and sunitinib as first-line treatment for metastatic kidney cancer

This multicentre analysis of axitinib versus sunitinib used as first-line treatment for metastatic renal cell carcinoma (RCC) in 169 patients shows that compared with sunitinib, axitinib significantly prolonged cancer-specific survival and overall survival. Axitinib also had a safer adverse event profile compared to sunitinib as a first-line therapy for previously untreated metastatic RCC. Read the […]

read more

Robot-assisted surgery available in East Lancashire

Three talented surgeons have performed what is believed to be the first combined renal and bowel cancer surgery in the North West using robotic surgery assisted by the Da Vinci robot. The surgery was performed at the Royal Blackburn Teaching Hospital, East Lancashire Hospitals NHS Trust. The patient was given pioneering surgery involving a partial […]

read more

Nivolumab-ipilimumab combination delays the need for additional treatment in kidney cancer patients

A recent analysis of data from the phase 3 Checkmate-214 clinical trial showed that first-line treatment with the nivolumab/ipilimumab combination significantly delayed the need for subsequent treatment in patients with advanced or metastatic renal cell carcinoma (RCC), compared with standard treatment with sunitinib. This benefit was also seen in patients who had stopped treatment, and […]

read more

Results from JAVELIN Renal 101 clinical trial – avelumab plus axitinib combination for advanced kidney cancer

The following article from Practice Update discusses the JAVELIN Renal 101 clinical trial, which compares avelumab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma (RCC). The article highlights the results of this particular trial and touches upon other combinations of vascular endothelial growth factor (VEGF) inhibitors with immunotherapy as having not just […]

read more

Promising avelumab plus axitinib data in renal cell carcinoma

The following OncLive interview with leading renal cell carcinoma (RCC) expert, Dr Toni Choueiri from the Dana-Farber Cancer Institute in Boston, US, discusses the data from the JAVELIN-101 study comparing the avelumab/axitinib combination with sunitinib in patients with previously untreated RCC. Dr Choueiri goes on to discuss where these data fit into the complex treatment paradigm of […]

read more

Historical outcomes in metastatic renal cell carcinoma

The following OncLive video interview with two leading renal cell carcinoma (RCC) experts, Dr Brian Rini, Cleveland Clinic Lerner College of Medicine, and Dr David McDermott, Harvard Cancer Center, summarises how the treatment and prognosis of metastatic RCC has changed over recent years, and looks forward to the advent of combination therapies in the future. Watch […]

read more
Showing 1 to 10 of 419 results
  TOP